Drugs / double-mutant heat-labile enterotoxin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02531802 | Oct 2015 → Jul 2017 | diarrheal disease | PATH | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | double-mutant heat-labile enterotoxin | “or without a double-mutant heat-labile enterotoxin (dmLT) as an adjuvant, in Bangladeshi children.” PMID 31757774 ↗ Nov 2019 |
| Known as | dmLT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02531802 ↗ |
| Modality | Protein / enzyme biologic | “dmLT, a derivative of wild-type enterotoxigenic Escherichia coli LT” NCT02531802 ↗ |
| Route | Oral | “administered orally on Day 0 and 14” NCT02531802 ↗ |